Dr. Vogelzang on Two Analyses of the ALSYMPCA Trial

Video

In Partnership With:

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial.

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial. The ALSYMPCA trial looked at radium-223 dichloride in patients with bone metastases from prostate cancer.

Vogelzang recently presented a study at the 2013 American Urological Association (AUA) Annual Meeting that showed reduction in the use of morphine, reduction in the need for radiation, and improvement in quality of life. Quality of life was measured using a standard method.

At the 2013 American Society of Clinical Oncology (ASCO) Meeting, Vogelzang presented a study looking at the effect on patients who have been treated with chemotherapy. The study analyzed what radium-223 did to the patients' blood counts and found that it had little effect.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD